Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting
-
Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference
-
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
-
Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
-
Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Therapeutic Areas
